Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOrthopedics/MusculoskeletalPriority Health knee osteoarthritis Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Modifiedpriority healthPolicy 91571

    OSTEOARTHRITIS OF THE KNEE

    Customize your policy alerts

    Sign up for priority health Policy 91571 alerts

    Get alerted when Policy 91571 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, limitations, and exclusions for diagnostic and therapeutic interventions for knee osteoarthritis, affecting providers delivering operative, interventional pain, and regenerative treatments.

    Policy Summary
    Payerpriority health
    PolicyOsteoarthritis of the Knee
    Policy CodePolicy 91571
    Change TypeCoverage status changesadded NMN listingsnew sections
    Effective DateAug 1, 2026
    Last ReviewMay 13, 2026
    Next Review DateMay 13, 2026
    Key ActionObtain prior authorization and document eligibility (KL II–IV, ≥6 months conservative care, and ≥50% pain relief from a diagnostic genicular nerve block) before genicular nerve RFA.
    SourceLink
    POLICY UPDATE CHANGES

    Added partial and total knee arthroplasty as medically necessary treatment for knee OA when Turning Point criteria is met.

    Added additional not medically necessary treatments, including Transcutaneous electrical nerve stimulation (TENS), Neuroablative therapies (e.g., cryoneurolysis), biomechanical shoe-based devices, implanted shock absorbers (e.g., MISHA®), synthetic cartilage implants, low-level laser therapy, and prolotherapy.

    Genicular nerve radiofrequency ablation moved from not medically necessary to medically necessary when strict criteria are met. Prior Authorization required.

    Removed a related policy that was retired (Autologous Chondrocyte Implant/Meniscal Allograft).

    Removed outdated references.

    New Policy scope section.

    New Medical/Professional Society Guidelines section.

    New Government Regulations section listing applicable CMS NCDs or LCDs.

    New FDA/Regulatory sections.

    Policy Language was added/removed/changed to better or more fully explain criteria.

    ≥50%Required pain relief from diagnostic block
    >=6 moConservative management duration
    KL II-IVImaging grade required for RFA
    movedRFA coverage status change
    severalNewly listed NMN treatments
    ~15Distinct therapies discussed

    Coverage Criteria and Determinations

    Genicular nerve RFA — medically necessary criteria

    Conventional thermal or cooled genicular nerve radiofrequency ablation (RFA) is considered medically necessary when ALL of the following criteria are met:

    Genicular nerve RFA criteria: 1) Documented symptomatic knee osteoarthritis confirmed by imaging demonstrating Kellgren-Lawrence grade II-IV disease; 2) Moderate to severe chronic knee pain resulting in functional impairment; 3) Failure of at least 6 months of conservative management (examples include structured physical therapy, NSAIDs, and intra-articular corticosteroid injections); 4) The individual is not an appropriate candidate for partial or total knee arthroplasty OR elects to defer arthroplasty; 5) Diagnostic genicular nerve block demonstrating at least 50% pain relief lasting a minimum of 24 hours.see node text

    Applies to conventional thermal or cooled RFA only.

    Operative and cartilage repair procedures — inclusions

    Procedures specifically listed as medically necessary when performed according to applicable TurningPoint clinical criteria:

    Inclusions list: Autologous chondrocyte implantation (e.g., Carticel®) for repair of articular cartilage defects; Knee resurfacing procedures (e.g., MAKOplasty®); Partial or total knee arthroplasty (knee replacement).

    These procedures require adherence to TurningPoint clinical criteria where applicable.

    Biomechanical shoe-based devices (AposHealth®)

    Coverage stance:

    AposHealth: Insufficient evidence supports clinical efficacy or long-term benefit; considered investigational and not recommended for routine clinical use.

    Available data limited by methodological weaknesses and lack of appropriate comparators.

    Cryotherapy / Cryoneurolysis

    Coverage stance:

    Cryoneurolysis: Evidence provides low to very low certainty of modest, inconsistent, or short-term pain relief; routine use is not supported and the intervention is considered experimental/investigational.

    Sham-controlled trials and meta-analyses show inconsistent benefits and limited durability.

    Custom-made lateral wedge insoles

    Coverage stance:

    Lateral wedge insoles: Evidence is mixed with modest, typically short-term benefit in selected subgroups; professional guidelines do not recommend routine use and the intervention is considered investigational for generalized knee OA.

    May provide benefit for selected patients with medial compartment OA when combined with arch support.

    Genicular artery embolization (GAE)

    Coverage stance:

    GAE: Preliminary studies report short-term symptom improvement but sham-controlled evidence is mixed and long-term benefit is uncertain; genicular artery embolization is classified as investigational and routine clinical use is not supported pending randomized data.

    Ongoing sham-controlled trials (e.g., GENESIS-2) are noted.

    Low-level laser therapy (LLLT)

    Coverage stance:

    LLLT: May provide short-term pain reduction, particularly as an adjunct to exercise, but evidence for function or structural benefit is low to very low; professional guidelines do not recommend routine use and LLLT is considered investigational for knee OA.

    Systematic reviews report short-term pain effects but inconsistent nonpain outcomes.

    Medial knee implanted shock absorber (MISHA® / ISA)

    Coverage stance:

    MISHA/ISA: Limited, primarily nonrandomized evidence shows short- to mid-term pain and function improvement and potential delay of arthroplasty in selected patients; considered emerging/investigational pending larger randomized trials.

    Preserves future arthroplasty options but lacks guideline endorsement.

    Osteochondral implant (CartiHeal Agili-C®)

    Coverage stance:

    Agili-C: FDA-approved for focal osteochondral lesions and supported for lesion-specific repair; not indicated or supported for routine treatment of generalized knee osteoarthritis and considered investigational for whole-joint OA management.

    Evidence derives from focal defect trials, not diffuse OA.

    Prolotherapy

    Coverage stance:

    Prolotherapy: Heterogeneous evidence with possible short-term pain and function improvement but inconsistent durability; professional societies do not support routine use and prolotherapy is considered investigational.

    Variability in protocols and injectates limits conclusions.

    Transcutaneous Electrical Nerve Stimulation (TENS) and related electrotherapies

    Coverage stance:

    TENS/NMES/electrotherapy: High-quality randomized trials do not show clinically meaningful benefit beyond placebo; major society guidelines recommend against routine use and these modalities are considered investigational/unproven for knee OA.

    Recent RCTs show no superiority over placebo.

    Genicular nerve radiofrequency ablation (RFA) / Cooled RFA

    Coverage stance and candidate selection:

    Genicular RFA coverage conditions: RCT meta-analyses indicate possible short-term pain and functional benefit (notably 6-24 weeks) with variable durability; candidate selection should include a diagnostic genicular nerve block demonstrating a clinically meaningful response (commonly ≥50% pain relief) and exclusion of patients who are imminent arthroplasty candidates.≥50% pain relief after diagnostic block

    Evidence certainty is low to very low; cooled RFA has not shown consistent superiority over conventional thermal RFA.

    Genicular nerve RFA coverage criteria

    Covered when ALL of the following are met

    RFA candidacy: Patient has knee osteoarthritis for which genicular nerve RFA is being considered.
    Diagnostic confirmation: Documented clinically meaningful response to a diagnostic genicular nerve block (commonly defined as >=50% short-term pain relief, typically lasting ≥24 hours).>=50%

    Diagnostic block-based enrichment is emphasized in clinical trials and guidance.

    Appropriate selection: Patient is not an imminent candidate for knee arthroplasty and has failed at least 6 months of conservative therapy; the procedure is intended as a selective, criteria-based intervention rather than a replacement for definitive surgical management.>= 6 months

    Conservative management examples include physical therapy, NSAIDs, and intra-articular corticosteroids.

    Genicular Nerve RFA — medically necessary with criteria

    Genicular nerve radiofrequency ablation coverage statement (summary):

    Genicular nerve RFA coverage: Genicular nerve radiofrequency ablation is medically necessary when strict criteria are met; prior authorization is required.

    Specific criteria are detailed elsewhere in the policy; prior authorization must document eligibility per policy requirements.

    The policy explicitly identifies three procedural limitations related to genicular nerve radiofrequency ablation (RFA) that are considered not medically necessary: pulsed RFA of the genicular nerves; repeat genicular nerve RFA when there is no documented clinically meaningful benefit from a prior ablation; and genicular nerve RFA in individuals with end-stage knee osteoarthritis when knee arthroplasty is imminently planned. These exclusions are intended to prevent use of approaches with inferior evidence (pulsed RFA) and to avoid repeated or duplicative ablations when prior treatment has not provided clear clinical benefit or when definitive surgical management is imminent.

    CartiHeal Agili-C® is a lesion-specific, resorbable osteochondral implant approved for focal articular cartilage and osteochondral defects. The policy clarifies that Agili-C is not indicated or supported for routine treatment of generalized knee osteoarthritis; its evidence base and regulatory labeling apply to contained, focal lesions and cannot be extrapolated to diffuse, whole-joint OA. Use of Agili-C for generalized OA is therefore considered investigational for the indications covered by this policy.

    The document lists multiple procedures and technologies as not medically necessary or investigational for routine management of knee OA. Examples include certain orthobiologic injectable therapies (adipose-derived regenerative cell therapies, BMAC, PRP, and mesenchymal cell injections), peripheral nerve–targeted neuromodulation such as TENS, neuroablative therapies including cryoneurolysis (e.g., Iovera®), mechanical/external off-loading devices (e.g., AposHealth® and custom lateral wedge insoles), genicular artery embolization (GAE), medial knee implanted shock absorbers (MISHA®), synthetic cartilage implants (CartiHeal Agili-C®), low-level laser therapy (LLLT), and prolotherapy. Corresponding billing codes for many of these interventions are also identified as considered not medically necessary in the coding section.

    The policy’s reference and evidence sections summarize existing bibliographic material about autologous therapies (adipose-derived injections, BMAC, PRP, and related mesenchymal cell approaches). These citations note heterogeneity in techniques, variable trial quality, and limited high-certainty evidence; however, the extracted bibliographic chunks do not by themselves state new, explicit coverage exclusions beyond those already summarized elsewhere in the policy text. The references provide supporting context for the policy’s investigational stance on these autologous biologic therapies.

    This update explicitly adds several therapies to the list of treatments considered not medically necessary or investigational: Transcutaneous Electrical Nerve Stimulation (TENS), neuroablative therapies (e.g., cryoneurolysis), biomechanical shoe-based devices (AposHealth®), implanted shock absorbers (e.g., MISHA®), synthetic cartilage implants (CartiHeal Agili-C® for generalized OA), low-level laser therapy (LLLT), and prolotherapy. The policy cites randomized trials, systematic reviews, and guideline statements as the basis for classifying these as experimental, investigational, or not supported for routine clinical use.

    In summary, the policy considers a broad set of interventions for knee osteoarthritis to be not medically necessary or investigational for routine care. This general list includes pulsed RFA, repeat ineffective genicular RFA, genicular RFA when arthroplasty is imminent, adipose-derived and other orthobiologic injectables (BMAC, PRP, MSCs), peripheral neuromodulation (TENS), neuroablative procedures (cryoneurolysis), biomechanical shoe-based devices and certain orthotics, genicular artery embolization (GAE), medial implanted shock absorbers (MISHA®), synthetic cartilage implants when used for generalized OA, low-level laser therapy (LLLT), and prolotherapy. The policy further cross-references specific CPT/HCPCS codes that are considered not medically necessary for these indications.

    A more detailed listing of interventions classified as investigational or not medically necessary includes: AposHealth® (biomechanical footwear), cryoneurolysis/cryotherapy, genicular artery embolization (GAE), low-level laser therapy (LLLT), medial implanted shock absorbers (MISHA®), prolotherapy, and TENS/electrotherapies. For most of these modalities the policy cites limited, heterogeneous, or low-certainty evidence and notes lack of endorsement from major professional society guidelines, supporting their investigational classification.

    The policy identifies a set of CPT/HCPCS and unlisted procedure codes to be considered in the context of the investigational or not medically necessary interventions. Representative codes listed as not medically necessary include 0232T (PRP injection), 0481T (autologous protein solution), 0552T (LLLT), 0565T/0566T (autologous adipose-derived cellular implants), 0737T (xenograft implantation), 20999 and 27599 (unlisted musculoskeletal procedures), 37242 (vascular embolization), 64640 (neurolytic peripheral nerve destruction), C8003 (medial knee implantable shock absorber), C9809 (cryoablation needle), E0720/L3649/L3000 (TENS/orthotic device codes), and M0076 (prolotherapy). These codes are flagged in the policy’s coding section as associated with treatments that are not supported for the indications covered here.

    Some extracted reference chunks contain bibliographic discussion of autologous and cell-based therapies but do not themselves include explicit, standalone 'not medically necessary' coverage determinations; rather, they provide evidence summaries, technique descriptions, and citations that the policy uses to justify its overall investigational stance. Thus, while the literature is cited extensively, several reference chunks serve primarily as evidence context rather than direct exclusion language.

    Prolotherapy and transcutaneous electrical nerve stimulation (TENS) are explicitly named among treatments considered not medically necessary in the policy text. The policy states that prolotherapy protocols are heterogeneous and that available trials show inconsistent, often short-term symptom benefits insufficient to support routine clinical use. Similarly, recent high-quality randomized evidence and guideline statements do not demonstrate clinically meaningful, durable benefit for TENS and related electrotherapies, supporting their classification as investigational or not medically necessary for knee OA.

    Procedures discussed in the referenced RFA and interventional sections do not list additional explicit billing codes in these specific chunks; coding details for covered and not-medically-necessary procedures are provided elsewhere in the policy’s coding tables. For operational purposes the policy maps procedural descriptions to the coding section rather than embedding code lists within the narrative RFA discussion.

    Coding and Billing

    Covered/Referenced CPT/HCPCS codesmixed
    27438Arthroplasty, patella; with prosthesis
    27446Arthroplasty, knee, condyle and plateau; medial OR lateral compartment
    27447Arthroplasty, knee, condyle and plateau; medial AND lateral compartments with or without patella resurfacing (total knee arthroplasty)
    27486Revision of total knee arthroplasty, with or without allograft; 1 component
    27487Revision of total knee arthroplasty, with or without allograft; femoral and entire tibial component
    64454Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed.
    64624Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed
    27412Autologous chondrocyte implantation, knee
    J7330Autologous cultured chondrocytes, implant
    Codes considered not medically necessary for the indications in the policymixedNot Covered
    0232TInjection(s), platelet rich plasma, any tissue, including image guidance, harvesting and preparation when performed
    0481TInjection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed
    0552TLow-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional
    0565TAutologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation
    0566TAutologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral
    0737TXenograft implantation into the articular surface
    20999Unlisted procedure, musculoskeletal system, general
    27599Unlisted procedure, femur or knee
    37242Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquired arterial malformations, arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms)
    64640Destruction by neurolytic agent; other peripheral nerve or branch (e.g., Iovera)
    1–10 of 16
    1/2
    No explicit CPT/HCPCS/ICD codes in these chunksmixed
    No codes listed
    inv-29: Diagnostic genicular nerve block response — >= 50% pain relief lasting >= 24 hours
    Threshold>= 50% pain relief
    Duration requirement>= 24 hours
    PurposeDiagnostic confirmation of genicular-mediated pain prior to RFA
    inv-30: Conservative management duration — >= 6 months
    Minimum duration>= 6 months
    Included therapiesPhysical therapy, pharmacologic management (e.g., NSAIDs), intra-articular injections (e.g., corticosteroids)

    Provider Actions, Authorization, and Denial Triggers

    Prior Authorization

    Prior authorization required for genicular nerve RFA

    Prior authorization is required when requesting conventional thermal or cooled genicular nerve radiofrequency ablation (RFA); the request must document that the member meets the policy's eligibility criteria (KL grade II–IV, chronic moderate-to-severe pain with functional impairment, ≥6 months conservative management, not an appropriate or electing to defer arthroplasty, and diagnostic genicular nerve block response ≥50% lasting ≥24 hours).

    • Document imaging-confirmed Kellgren-Lawrence grade II–IV disease
    • Document failure of ≥6 months of conservative management
    • Document diagnostic genicular nerve block response (≥50% pain relief ≥24 hours)
    • Confirm patient is not an imminent arthroplasty candidate or elects to defer arthroplasty
    Prior Authorization

    Confirm diagnostic genicular nerve block response

    Prior authorization should include documentation that a diagnostic genicular nerve block demonstrating a clinically meaningful response (commonly defined as ≥50% pain relief) was performed prior to approving genicular nerve RFA.

    Background and Rationale

    Knee osteoarthritis (OA) is a degenerative joint disorder characterized by activity-related knee pain, stiffness, swelling, and functional limitation. Radiographic severity is commonly classified using the Kellgren-Lawrence (KL) grading system, where KL grades II–IV represent definitive to severe disease and are used in this policy to define imaging eligibility for certain interventions. Core nonpharmacologic management—structured exercise, education, and weight management—forms the foundation of OA care, with pharmacologic therapies used as adjuncts. Genicular nerve procedures such as radiofrequency ablation are positioned as targeted, minimally invasive options for symptom relief in appropriately selected patients who have failed conservative therapy and are not immediate candidates for arthroplasty.

    Definitions and Key Terms

    inv-55: Kellgren-Lawrence (KL) grade — radiographic classification; KL II-IV referenced for RFA candidacy
    DefinitionRadiographic classification system for knee OA severity (Kellgren-Lawrence, KL)
    KL grades referenced for RFA candidacyKL II-IV
    Clinical meaningGrades II-IV indicate definitive to severe OA (osteophytes, joint-space narrowing, sclerosis)
    inv-56: Genicular artery embolization (GAE) — definition
    DefinitionCatheter-based, image-guided embolization of hyperemic genicular arterial branches to reduce synovial hypervascularity and nociceptive signaling
    SettingTypically outpatient under moderate sedation
    Policy Summary
    Payerpriority health
    PolicyOsteoarthritis of the Knee
    Policy CodePolicy 91571
    Change TypeCoverage status changesadded NMN listingsnew sections
    Effective DateAug 1, 2026
    Last ReviewMay 13, 2026
    Next Review DateMay 13, 2026
    Key ActionObtain prior authorization and document eligibility (KL II–IV, ≥6 months conservative care, and ≥50% pain relief from a diagnostic genicular nerve block) before genicular nerve RFA.
    SourceLink
    On This Page
    Coverage Criteria and DeterminationsCoding and BillingProvider Actions, Authorization, and Denial TriggersBackground and RationaleDefinitions and Key Terms
    Purpose
    Document failure of conservative management before considering genicular nerve RFA
    inv-31: Diagnostic genicular nerve block response (alternate extraction) — ≥50% pain relief
    Responder threshold≥50% pain relief
    Assessment timingShort-term pain relief following image-guided anesthetic injection
    UsePrognostic step to identify candidates likely to benefit from genicular nerve RFA
    inv-32: Diagnostic genicular nerve block responder threshold — >= 50% short-term pain relief
    Responder threshold>= 50% short-term pain relief
    MethodImage-guided injection of local anesthetic adjacent to targeted genicular nerves
    RoleRequired prognostic step prior to genicular nerve ablation to enrich for responders
    • Include results of image-guided diagnostic genicular nerve block
    • Specify magnitude and duration of pain relief observed after the block
    Prior Authorization

    Submit medical necessity justification with prior authorization

    Providers must submit a prior authorization request per Priority Health procedures and include medical necessity justification and supporting documentation (use TurningPoint authorization criteria lookup when applicable).

    • Submit medical necessity rationale and required supporting records
    • Use Priority Health Provider Manual and TurningPoint Authorization Criteria Lookup
    Note

    Authorization requirements for other therapies may vary

    Some therapies described elsewhere in the policy do not have specified prior authorization requirements in the extracted reference material; check product-specific rules and the Priority Health Provider Manual for authorization details.

    • Verify authorization requirements for non-RFA interventions in the Provider Manual
    Prior Authorization

    Genicular nerve RFA requires prior authorization and criteria

    Genicular nerve radiofrequency ablation requires prior authorization and is covered only when the policy's strict coverage criteria are met; the policy was revised to change RFA from not medically necessary to medically necessary with criteria.

    • Prior authorization is mandatory for genicular nerve RFA
    • Coverage only when all specified eligibility criteria are documented
    Step Therapy

    Document ≥6 months of conservative management

    Prior authorization must demonstrate failure of at least 6 months of conservative management (examples include physical therapy, NSAIDs, and intra‑articular corticosteroid injections) before genicular nerve RFA is approved.

    • Document duration and type of conservative therapies tried (e.g., PT, NSAIDs, intra‑articular corticosteroids)
    • Indicate dates and clinical response to those therapies
    Step Therapy

    RFA sequencing: conservative therapy → diagnostic block → RFA

    Genicular nerve RFA is intended for patients who are not immediate candidates for arthroplasty and typically requires a prognostic diagnostic nerve block and sequencing after conservative therapy.

    • Confirm patient is not an appropriate or imminent arthroplasty candidate or has elected to defer arthroplasty
    • Ensure diagnostic genicular nerve block was performed as part of sequencing
    Prior Authorization

    Diagnostic genicular nerve block required before ablation

    A diagnostic genicular nerve block is required as a prognostic step to confirm genicular-mediated nociceptive pain before proceeding to genicular nerve RFA.

    • Perform image-guided diagnostic GNB targeting the intended genicular nerves
    • Record pain relief magnitude and duration following the block
    Note

    No additional step therapy requirements specified

    The extracted reference material does not describe additional formal step therapy programs beyond the conservative management and diagnostic‑block sequencing required for RFA; check policy and benefits for any plan-specific step edits.

    • No other formal step therapy requirements specified in these chunks
    Documentation Required

    Required documentation for genicular nerve RFA

    Documentation submitted for genicular nerve RFA must show imaging-confirmed Kellgren‑Lawrence grade II–IV disease, chronic moderate‑to‑severe pain causing functional impairment, failure of ≥6 months of conservative therapy, and diagnostic genicular nerve block demonstrating ≥50% pain relief lasting ≥24 hours.

    • Include imaging report confirming KL grade II–IV
    • Detail pain severity, functional impairment, and duration
    • Provide records of conservative treatments and dates
    • Attach diagnostic genicular nerve block procedure notes and pain relief metrics (magnitude and duration)
    Documentation Required

    Document diagnostic block response and imaging guidance

    To document RFA candidacy, include contemporaneous procedural records showing the diagnostic genicular nerve block response (commonly defined as ≥50% short‑term pain relief) and imaging guidance confirming the targeted nerves.

    • Attach diagnostic GNB procedure note with percent pain relief and duration
    • Document imaging modality and confirmation of needle placement
    Denial Risk

    No documentation or administrative prior authorization risks denial

    If no documentation or administrative prior authorization is provided to demonstrate that strict coverage criteria are met, requests for genicular nerve RFA risk denial.

    • Absence of required documentation may lead to claim denial
    • Ensure prior authorization includes all eligibility evidence to avoid administrative denials
    Documentation Required

    Required documentation for RFA candidacy — failure may lead to denial

    Providers must document failure of conservative management and positive diagnostic block response to support RFA candidacy; lack of these required elements will place the request at high risk for denial.

    • Failure to show ≥6 months conservative therapy is a denial risk
    • Failure to show diagnostic block ≥50% relief is a denial risk
    Denial Risk

    Denial triggers: Not medically necessary RFA indications

    Requests for procedures listed as Not Medically Necessary (for example, pulsed RFA, repeat genicular RFA without documented prior benefit, or genicular RFA when arthroplasty is imminently planned) may be denied.

    • Pulsed RFA of genicular nerves is considered not medically necessary
    • Repeat RFA without documented prior clinically meaningful benefit is not medically necessary
    • RFA when arthroplasty is imminent is not medically necessary
    Denial Risk

    Denial risk for investigational therapies

    Interventions considered experimental, investigational, or unproven (e.g., AposHealth®, cryoneurolysis/cryotherapy, genicular artery embolization, medial knee implanted shock absorbers, Agili‑C for generalized OA) are at high risk for denial when requested as routine OA treatments.

    • These therapies are classified as investigational and not supported for routine OA care
    • Requests will likely be denied absent an approved individual case review
    Denial Risk

    Experimental/investigational interventions require prior plan approval

    Requests for interventions deemed experimental, investigational, or unproven will be denied unless an individual case review with prior plan approval is obtained and a Priority Health medical director or clinical pharmacist authorizes coverage.

    • Submit case for individual plan review and prior approval to pursue investigational interventions
    • Coverage exceptions require review and approval by plan medical leadership
    Note

    Evidence and references available to support requests

    This policy includes an evidence/reference list; providers may cite the listed references when supporting medical necessity requests, but references alone do not substitute for the required contemporaneous clinical documentation.

    • Use cited randomized trials and guidelines to support rationale, but include member-specific clinical documentation in the authorization request
    Denial Risk

    Genicular nerve RFA: prior authorization and denial risk

    Requests for genicular nerve RFA may be denied if strict coverage criteria are not met; prior authorization is required and must include the documentation elements specified in the policy.

    • Ensure all eligibility criteria evidence is included in the prior authorization to avoid denial
    Denial Risk

    Denial risk: listed not medically necessary treatments

    Treatments listed as not medically necessary in the policy (including transcutaneous electrical nerve stimulation, neuroablative therapies such as cryoneurolysis, biomechanical shoe-based devices, implanted shock absorbers, synthetic cartilage implants, low-level laser therapy, and prolotherapy) will be denied when requested for knee osteoarthritis.

    • Do not submit prior authorization for interventions explicitly listed as not medically necessary unless requesting an individual case review
    • Include supporting rationale and request prior plan approval if seeking exception
    Note
    Note
    Evidence summaryEarly observational studies report symptomatic improvement; sham-controlled trial data are mixed and long-term benefit uncertain
    inv-57: Genicular nerve radiofrequency ablation (RFA) — definition
    DefinitionMinimally invasive ablative procedure that thermally disrupts sensory genicular nerve transmission to reduce knee OA pain
    ModalitiesIncludes conventional thermal RFA and cooled RFA; pulsed RFA is mechanistically distinct and less effective
    TargetsSuperomedial (SM), superolateral (SL), and inferomedial (IM) genicular nerves
    inv-58: Medial Implanted Shock Absorber (MISHA® / ISA) — definition
    DefinitionExtra-articular, subcutaneous load-absorbing implant placed medial to the knee to offload the medial compartment without altering joint anatomy
    IndicationIntended for symptomatic medial tibiofemoral OA in patients who failed conservative therapy and are not yet arthroplasty candidates
    EvidenceLimited, primarily nonrandomized studies with low-to-moderate certainty; may delay arthroplasty in selected patients
    inv-59: Genicular nerve block (GNB) — definition and diagnostic role
    DefinitionImage-guided injection of local anesthetic adjacent to targeted genicular nerves used diagnostically to confirm genicular-mediated pain
    Responder criterionTypically defined by achievement of ≥50% short-term pain relief following the block
    RoleUsed as a required prognostic step before proceeding to genicular nerve RFA
    inv-60: Conventional thermal RFA — definition
    DefinitionContinuous heat ablation delivering temperatures around 70-90°C to thermocoagulate sensory nerve fibers
    Clinical noteCommon conventional modality for genicular nerve RFA
    ComparisonPulsed RFA is inferior; cooled RFA may create larger lesions but not consistently superior clinically
    inv-61: Cooled RFA — definition
    DefinitionRFA technique using internal coolant to keep probe temperatures lower (~60°C) while generating larger, more uniform lesions via heat dispersion
    Clinical contextMay offer modest incremental benefit but randomized trials have not consistently shown superiority over conventional thermal RFA
    Regulatory noteReferenced in device-specific literature (e.g., Coolief®) and clinical trials
    inv-62: Pulsed RFA — definition and note of inferior outcomes
    DefinitionNon-destructive RFA approach operating near 42°C that does not thermocoagulate nerves
    Outcome noteDemonstrated inferior and less durable clinical outcomes compared with thermal RFA modalities
    RoleNot recommended as preferred ablative technique for genicular nerve RFA due to lower effectiveness
    inv-63: Autologous microfragmented adipose injection / adipose-derived therapies — definition
    DefinitionTherapies using processed autologous adipose tissue or adipose-derived mesenchymal stromal cells delivered intra-articularly for knee OA
    Regulatory/evidence noteDevice techniques and evidence summarized in HTA and clinical reports; evidence remains heterogeneous and is considered investigational
    Relation to policyListed among autologous adipose-derived regenerative therapies discussed in references
    inv-64: BMAC and PRP — definition and evidence summary placeholder
    DefinitionBone marrow aspirate concentrate (BMAC) and platelet-rich plasma (PRP) injections for symptomatic knee osteoarthritis
    Evidence summaryMultiple randomized trials and systematic reviews cited; comparative effectiveness varies across studies
    Policy contextDiscussed in evidence section; considered investigational/not routinely recommended depending on indication
    inv-65: Genicular artery embolization — definition (additional)
    Definition (additional)Endovascular embolization of genicular arteries to treat OA-related knee pain by reducing synovial hypervascularity
    EvidenceSystematic reviews and randomized trial protocols (e.g., GENESIS-2) noted; sham-controlled data are mixed
    Technique noteTarget vessel selection and embolic materials vary across studies
    inv-66: Genicular nerve block / radiofrequency ablation — definition (additional context)
    Definition (additional)Peripheral nerve block and subsequent radiofrequency ablation targeting genicular nerves to reduce knee OA pain; block used as prognostic step
    EvidenceSham-controlled RCT meta-analyses show short-term pain and functional benefits at 12-24 weeks; overall certainty low to very low
    Practice implicationDiagnostic GNB typically required to document clinically meaningful response before RFA
    inv-67: Cooled radiofrequency ablation (cooled RFA) — definition and regulatory context
    DefinitionCooled radiofrequency ablation uses cooled probes to create larger, more uniform lesions at lower probe temperatures; marketed for genicular nerve RFA (e.g., Coolief®)
    Regulatory contextReferenced in device literature and randomized trials; compared with conventional thermal RFA in multicenter trials (e.g., COCOGEN)
    Evidence summaryRandomized trials show clinically meaningful pain reduction with cooled RFA, but superiority over conventional RFA is not consistently demonstrated